Shivaani Kummar, MD, FACP
Oregon Health & Science University
Session Chair
Financial Disclosure
Incyte, SillaJen Inc., Deciphera Pharmaceuticals LLC, Moderna Inc, AstraZeneca LP, Immunitas Therapeutics, Inc., Transcenta Therapeutics, Inc., Bristol Myers Squibb, Adanate, Inc., 23andMe Inc., Gilead Sciences Inc., DOT Therapeutics-1 Inc., PMV Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Blueprint Medicines Corp., Parabilis Pharmaceuticals, Nuvectis Pharma, Inc.
Researcher
Springworks Therapeutics, SeaGen, Bayer, Genome & Company, HarbourBiomed, BPGbio Therapeutics, Oxford Biotherapeutics, Mundibiopharma, BPGbio, Inc., Gilead, Mirati; GI Innovation Inc, XYone Therapeutics, Genome Insight, Aadi Biosciences, MOMA Therapeutics, Daiichi Sankyo, Parabilis, Boehringer Ingelheim Pharmcaeuticals
Consultant
PATHOMIQ (co-founder), Fortress Biotech, Inc (equity), Sift Biosciences (Equity)
Ownership Interest